Pediatrix Medical Group Inc. 's shares fell 1.2% in pre-market trading on Tuesday after Jefferies downgraded the stock to Hold from Buy, citing limited near-term upside despite recent operational improvements.
Firmanın акції останнім часом котирувалися на рівні 26,25 долара, знижуючись від 52-титижневого максимуму в 27,94 долара, досягнутого раніше в сеансі. За останні два роки, Pediatrix зросла приблизно на 150%, включаючи зростання на 61% за останні 12 місяців, що перевищує показники більш широких ринкових показників.
Jefferies maintained a positive long-term outlook, raising its price target to $28 from $27, albeit the downgrade reflects concerns over earnings growth constraints. Analysts noted that while management has made progress in exiting underperforming outpatient operations and resolving revenue cycle management issues, an anticipated headwind from enhanced Affordable Care Act premium tax credit changes may cap near-term earnings growth.
Pediatrix reported adjusted earnings per share of $0.63 and revenue of $488 million for the second quarter of 2026. The full-year 2026 adjusted EBITDA guidance was reaffirmed in a range of $280 million to $300 million, unchanged from the previous projections.
Broad market showed mixed signals, with the S&P 500 up 0.1% and the Nasdaq essentially flat in early trading. Pediatrix's stock performance remains closely linked to healthcare services demand and regulatory dynamics affecting reimbursement rates and operational efficiency.
